MultivisionDx builds AI-powered decision-support tools for personalized diagnosis and treatment selection for solid cancer. Our computer vision technology integrates unique biological and spatial features of the tumor and its microenvironment, generating patient-specific tumor profiles for each patient.
This approach allows clinicians to assess tumor aggressiveness and tailor the most effective treatment strategies for individual patients.
Built on years of multidisciplinary research at the University of Helsinki and demonstrated in a 650-patient proof-of-concept study published in Cell, the technology now carries pending patents for both its biomarker-discovery platform and a first-in-class composite biomarker for head-and-neck cancer, establishing a new standard in tumor profiling.
MultivisionDx launches as a spinout from the University of Helsinki following a successful Research-to-Business project
Supported by University of Helsinki and Business Finland
Research to Business funding granted for two year commercialization project